NUS spinout MediSix has obtained $20m from investors including Osage University Partners to commercialise research into leukaemia and lymphoma treatments.

MediSix Therapeutics, a Singapore-based cell therapy spinout from National University of Singapore (NUS), closed a $20m series A round yesterday that featured spinout-focused investment firm Osage University Partners.

The round was led Lightstone Ventures and also included Singaporean state-owned investment firm Temasek.

MediSix is developing an immunotherapy that targets lymphoma and leukaemia. It is also commercialising a cell engineering platform that is expected to enable applications beyond T-cell malignancies.

The company is based on research by founder Dario Campana, professor…